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Abstract
Aim of the study: To evaluate the frequency of MRE11/RAD50/NBS1 (MRN)-complex loss of protein expression in
endometrial cancers (EC) and to determine whether loss of MRE11 renders the cancer cells sensitive to Poly(ADP-ribose)
polymerase (PARP)-inhibitory treatment.
Methods: MRN expression was examined in 521 samples of endometrial carcinomas and in 10 cancer cell lines. A putative
mutation hotspot in the form of an intronic poly(T) allele in MRE11 was sequenced in selected cases (n = 26). Sensitivity to
the PARP-inhibitor, BMN673 was tested in colony formation assays before and after MRE11 silencing using siRNA.
Homologous recombination (HR) DNA repair was evaluated by RAD51-foci formation assay upon irradiation and drug
treatment.
Results: Loss of MRE11 protein was found in 30.7% of EC tumours and significantly associated with loss of RAD50, NBS1 and
mismatch repair protein expression. One endometrial cell line showed a markedly reduced MRE11 expression due to a
homozygous poly(T) mutation of MRE11, thereby exhibiting an increased sensitivity to BMN673. MRE11 depletion sensitizes
MRE11 expressing EC cell lines to the treatment with BMN673. The increased sensitivity to PARP-inhibition correlates with
reduced RAD51 foci formation upon ionizing radiation in MRE11-depleted cells.
Conclusion: Loss of the MRE11 protein predicts sensitivity to PARP-inhibitor sensitivity in vitro, defining it as an additional
synthetic lethal gene with PARP. The high incidence of MRE11 loss in ECs can be potentially exploited for PARP-inhibitor
therapy. Furthermore, MRE11 protein expression using immunohistochemistry could be investigated as a predictive
biomarker for PARP-inhibitor treatment.
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Introduction
Endometrial cancer (EC) is the fourth most common malig-
nancy among women. The majority of ECs are diagnosed in early
stage and are associated with very favourable overall prognosis [1].
Treatment options, however, for advanced, recurrent or meta-
static ECs, are limited and consist mainly of cytotoxic chemother-
apy [1]. Potential targeted treatments are under clinical investi-
gations but have not yet been incorporated in routine clinical use
[2].
EC is a heterogeneous disease with distinct histological and
molecular characteristics [2]. So far, EC have been classified into
types I and II. This is based on the different histological properties
(endometrioid vs. non-endometrioid) and on the clinical prognosis
(favourable vs. poor) [2,3]. In addition, distinct molecular
alterations occur preferentially in either type I or type II EC
(reviewed in [2]). Whereas type I tumours are characterized by
microsatellite instability (MSI) and polymutations in different types
of genes, almost all type II tumours harbour mutations of the
tumour suppressor gene TP53 [4]. Recently, novel molecular
subgroups have been described in a way akin to breast cancer [5].
Based on their mutation profile and copy-number changes ECs
are categorized into: the ultramutated, the hypermuted, the copy
number low and the copy number high subgroup [5].
The hypermutated subgroup includes mostly endometrioid EC,
all harbouring microsatellite instability (MSI). These tumours are
known to develop mutations in various other genes (hypermutated
genome) but also those involved in the DNA double strand break
(DSB) repair machinery [6]. One of the most common recurrent
mutation is found in the MRE11 gene, whose product is a part of
the MRE11-RAD50-NBS1 (MRN)- complex that is involved in
the detection and repair of DNA double-strand breaks (DSBs)
[7,8]. MRE11 germline mutations that cause a lethal phenotype in
mice [9] are rarely encountered in humans and lead to an Ataxia
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telangiectasia-like disorder (ATLD) [10]. Somatic mutations in
MRE11, however, are frequently detected in colorectal cancers
with MSI and have also been suggested for MSI-positive ECs [11].
Mutations of the intronic poly(T) sequence of MRE11 between
exons 4 and 5 are frequent events in MSI positive colorectal und
ECs [11,12]. In EC, MSI is present in more than 20% of tumours
and is mainly caused by epigenetic silencing of the MMR gene
MLH1 [13]. This leads to changes in the number of nucleotide
repeats found in coding and non-coding elements of many genes
such as MRE11 [14].
Synthetic lethality occurs when two individually occurring
mutations have no effect on cell viability, but cause cell death in
combination [15,16]. Inhibition of a synthetic lethal partner gene
in cancer cells presenting a synthetic lethal mutation may prove an
attractive strategy to develop specific anti-cancer drugs with
minimal side effects in healthy tissue. Recent studies have revealed
that cancers with loss of function of BRCA1 or BRCA2 show
exquisite sensitivity to Poly(ADP-ribose) polymerase (PARP)-
inhibitors [17,18]. Given that MRE11 is involved in DNA DSB
repair through the MRN-complex, loss of function of this complex
through inactivating mutations might lead to sensitivity to PARP-
inhibitors [19]. PARP1, a DNA repair enzyme, has been
implicated in the repair of DSBs. PARP inhibition leads to
apoptosis or senescence in cells where DNA repair by homologous
recombination (HR) is impaired (synthetic lethality). For this study
we used a potent selective PARP1-inhibitor BMN673, that has
shown very encouraging results in phase I/II trials [20].
Here we show that MRN is frequently lost in EC, which leads to
increased PARP inhibitor sensitivity. This may be exploited for
treatment of patients with EC harbouring loss of the MRN-
complex. The goal of this study is to show the frequency of loss of
MRE11 and MRN-complex in EC and whether this leads to
increased sensitivity to PARP-inhibitors exploiting MRE11 as a
potential synthetic lethal gene.
Materials and Methods
Tissue Microarrays
Tissue microarrays (TMAs) with formalin-fixed and paraffin
embedded endometrial carcinomas were constructed previously
[21]. Two cohorts from the Institutes of Surgical Pathology,
University Hospitals Basel and Zurich (Switzerland) containing
339 (Basel-TMA) and 182 (Zurich-TMA) cancer samples were
included in this study. Clinical and pathological characteristics
were taken from the clinical databases and pathology records.
Routine hematoxylin and eosin sections were performed for
histopathological evaluation. The stage of tumours was assessed
according to the International Federation of Gynaecology and
Obstetrics (FIGO) and TNM staging system. Histological subtype
and tumour grade were defined according to the WHO
classification 2003. Follow-up data are known from 480 patients.
The median follow-up time was 31.5 months (range, 1–184) for
the Basel cohort, and 45 months (range, 1–124) for the Zurich
cohort. Patients with localized disease were treated by hysterec-
tomy and bilateral salpingectomy (with or without pelvic and
paraaortic lymphadenectomy). Vaginal radiation therapy was
postoperatively administered when invasion of the myometrium or
tumour grade 3 was evident. The study was approved for both
cohorts by the local scientific ethics committee (KEK-ZH-NR:
2010-0358). Baseline characteristics of patients with EC are
summarized in Table 1.
Immunohistochemistry
After antigen retrieval, the slides were incubated with the
following antibodies: MRE11 (clone 31H4, cell signalling, no.
4847, 1:500), RAD50 (13B3/2C6, Abcam limited, no. ab89,
1:500), NBS1 (cell signalling, no. 3002, 1:50), MLH1 (G168-15,
PharMingen, Becton Dickinson, 1:100), MSH2 (25D12, Novocas-
tra Lab. Ltd, 1:100), PMS2 (A16-4, PharMingen, Becton
Dickinson, 1:300), and MSH6 (44, BD Biosciences, 1:500). After
incubation for 1 hour at room temperature, the staining of
MRE11, RAD50, and NBS1 was further conducted with the
Ventana Benchmark automated system (Ventana Medical Sys-
tems, USA) using Ventana reagents as well as UltraMap DAB
Table 1. Immunohistochemical expression of MRE11, RAD50, NBS1-p95, and mismatch repair proteins.
Immunohistochemical expression n (%)
MRE11 (n =430)
negative 132 (30.7)
positive 298 (69.3)
RAD50 (n=440)
negative 107 (24.3)
positive 333 (75.7)
NBS1-p95 (n =433)
negative 127 (29.3)
positive 306 (58.7)
MSH2/MSH6 (n=487)
negative 112 (23.0)
positive 375 (77.0)
MLH1/PMS2 (n=497)
negative 139 (28.0)
positive 358 (72.0)
doi:10.1371/journal.pone.0100041.t001
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detection kit. The antibodies against the mismatch repair proteins
were incubated for 30 minutes and the staining procedure was
carried out with the automated Leica BOND system using Bond
Polymer Refine Detection Kit (Leica Biosystems). The expression
analysis was performed by two pathologists (AN, KI). The nuclear
immunoreactivity of MRE11, RAD50, and NBS1 was scored as:
negative (0), weak (1), moderate (2) and strong (3). The protein
expression of the mismatch repair genes was considered as positive
when nuclear staining was evident. Stromal cells showing nuclear
staining were used as a positive control.
Cancer Cell Lines and Growth Conditions
The EEC cell lines Hec-108 [22] and Hec-116 [22] were grown
in MEM, HEC 1A (ATCC) in McCoy’s, EFE-184 (DSMZ) in
RPMI, AN3CA (ATCC) in DMEM, ARK-II [23] in DMEM,
SNG-II [24] in DMEM, ECC-1 [25] in RPMI 1640, and were a
gift from Uwe Schirmer, DKFZ. HEC6-ST3 [22], grown in
MEM, and KLE (ATCC), grown in DMEM/F-12, were a gift
from Jaqueline Galeas, UCSF. The media were supplemented
with 10% (medium for ECC-1 with 5%) (v/v) fetal bovine serum
and with either penicillin (100 U/ml)/streptomycin (60 mg/ml) or
antibiotic-antimycotic, and maintained at 37uC in a humidified
atmosphere at 5% CO2. All cell culture material was purchased
from Gibco by LifeTechnologies.
Immunoblotting
Whole-cell protein extracts were prepared from cells lysed with
an SDS lysis buffer. Western blotting was performed with primary
antibodies against MRE11 (D151, gift from Steve Jackson,
Cambridge), RAD51 (rabbit polyclonal antibody, Santa Cruz
Biotechnology), NBS1 (mouse monoclonal antibody, GeneTex),
beta-tubulin (mouse monoclonal antibody, Sigma). Incubation
with the primary antibody was followed by incubation with an
HRP-conjugated secondary antibody (anti-mouse and anti-rabbit
HRP from Sigma, anti-sheep HRP from SantaCruz) and
chemiluminescent detection of proteins (Amersham).
MRE11 Mutation Analysis
Thirteen MRE11 immunohistochemistry (IHC) positive and 13
IHC negative samples were chosen from the Zurich cohort for
MRE11 mutation analysis. Three tissue cylinders (diameter
0.6 mm) were punched from each paraffin block for DNA
extraction. Genomic DNA was extracted using the DNeasy Blood
& Tissue Kit (Qiagen, Hilden, Germany). The concentrations of
the obtained nucleic acids were measured using the Nanodrop
Table 2. MRE11 mutation analysis in endometrioid and serous endometrial carcinoma samples.
Sample No. Histological subtype p53 protein expression MRE11 protein expression
MRE11 protein
intensity
MRE11 poly(T)
alleles
en1 Endom strong positive 2 T11
en2 Serous positive 3 T11
en3 Endom neg positive (low) 1 T11
en8 Endom neg negative 0 T11
en9 Endom strong positive 2 T11
en10 Serous negative 0 T11
en11 Endom low negative 0 T10–11
en12 Endom low positive (low) 1 T9–10
en13 Endom strong positive 2 T11
en14 Endom neg negative 0 T11
en15 Endom strong positive 2 T11
en16 Endom neg negative 0 T11
en17 Endom low positive 2 T11
en18 Endom neg positive 3 T11
en19 Endom low positive 2 T11
en20 Endom strong positive (low) 1 T11
en21 Endom low negative 0 T11
en22 Endom neg positive (low) 1 T11
en23 Endom neg positive (low) 1 T11
en26 Endom neg negative 0 T9
en28 Endom strong negative 0 T11
en30 Endom neg negative 0 T10–11
en34 Endom neg negative 0 T11
en38 Endom low negative 0 T10–11
en40 Endom neg negative 0 T11
en62 Endom strong negative 0 T11
The immunohistochemistry status of p53 and MRE11 and the nuclear immunoreactivity of MRE11 are shown. Immunoreactivity of MRE11 was scored as: negative (0),
weak (1), moderate (2), and strong (3).
doi:10.1371/journal.pone.0100041.t002
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(Thermo Fisher Scientific, Waltham, MA, USA). PCR was
performed as previously described (Grannini et al., 2002) with a
slight modification. Only 50 ng of genomic DNA were PCR-
amplified. DNA sequencing was carried out by using the BigDye
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). The
obtained sequences were analyzed for mutations in the poly(T)11
repeat region within the human MRE11 intron 4 (Table 2).
Colony Formation Assays
Long-term survival assays were performed as previously
described [26]. In brief, cells were seeded in six-well plates in
triplicates at a concentration of 300–2000 cells per well and
treated with the inhibitor after 24 hours, being continuously
exposed to the drug (10211 to 1026 M) dissolved in dimethyl
sulfoxide (DMSO) (control: DMSO). Media and drug were
replaced every 3 to 5 days. After 10 to 15 days, the cells were
fixed with TCA 10% and stained with sulforhodamine B (SRB)
(Sigma) and a colorimetric assay was performed as described
previously [26]. The PARP inhibitor BMN673 was a gift from
Biomarin Pharmaceuticals, USA. Mirin was purchased from
Calbiochem.
siRNA And Transfections
To knock down human MRE11 we used three different siRNAs
(Microsynth, Switzerland) using RNAimax (Gibco by Life-
Technologies) according to the manufacturer’s instructions. The
target sequences (sense) were: GCUAAUGACUCUGAU-
GAUATT [27], GAGCAUAACUCCAUAAGUATT [28], and
GAUGCCAUUGAGGAAUUAGTT [29]. As a control, cells
were transfected with siRNA against luciferase (sense):
CGUACGCGGAAUACUUCGATT. Cells were seeded 48 hours
after transfection and treatment started 72 hours after transfection
(PARP inhibitor, irradiation).
Analysis of RAD51 Foci Formation
Nuclear RAD51 foci were visualized and quantified as
previously described [26] and used as surrogate markers for
induction of DNA DSBs and competent HR DNA repair,
respectively. In brief, cells were grown on coverslips (12 mm,
Thermo Scientific) and exposed to 10 Gy of IR. After 4–6 hours
recovery, the cells were fixed, permeabilized, and immunostained
with primary antibodies against RAD51 (polyclonal rabbit
antibody, Santa Cruz) and detected with alexa flour 488
(Invitrogen). Nuclei were counterstained with 49,6-diamidino-2-
phenylindole (DAPI). The presence of RAD51 foci was evaluated
in a minimum of 100 cells in three independent experiments with
an automated inverted fluorescence microscope (LEICA–
DMI6000 B).
Statistical Analysis
The statistical evaluation was performed with the SPSS software
Version 21.0 (SPSS Inc., Chicago, IL, USA). The scoring data of
MRE11, RAD50, and NBS1 were dichotomized into ‘‘negative’’
(no expression) and ‘‘positive’’ (weak, moderate, or strong
expression). The statistical significance of the association between
these molecules, and the mismatch repair protein expression as
well as clinicopathological parameters was assessed by Chi2 test for
trends and Fisher’s exact test. In addition, Spearman’s correlation
was used to evaluate an association between MRE11, RAD50,
NBS1, and mismatch repair proteins. The probability of overall
survival as a function of time was determined by the Kaplan-Meier
method. Differences in the survival curves were compared by the
log rank test. Sensitivity curves were calculated in GraphPad Prism
Figure 1. MRE11 protein expression in endometrial carcinomas as assessed by immunihistochemistry. A, negative (complete loss of
MRE11 protein expression); B, + (weak nuclear expression); C, ++ (intermediate nuclear expression); D, +++ (strong nuclear expression).
doi:10.1371/journal.pone.0100041.g001
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Version 6 (GraphPad Software Inc., La Jolla, USA) and statistical
differences between IC50 values were assessed using F-tests.
Generally, p-values smaller 0.05 were considered as significant.
Results
MRN-complex Expression and the Association with
Mismatch Repair Protein Status and Clinicopathological
Factors
Immunohistochemical analysis of MRE11, RAD50, and NBS1
was successful in 456, 466, and 458 endometrial carcinomas,
respectively, due to the lack of tumour tissue in some TMA spots.
All molecules showed a nuclear staining pattern. Among the 521
endometrial carcinomas patients 30.7% (132/430) showed a
complete loss of MRE11 (Fig. 1A, and Table 1). Expression loss
of MRE11 significantly correlated with protein loss of the other
MRN-complex members RAD50 and NBS1. Loss of any MRN-
complex protein was also significantly associated with mismatch
repair protein expression as well as with FIGO stage and histologic
grading (Table 3). In Kaplan-Meier analysis, FIGO stage,
histological subtype, grading and patient age were prognostic
factors (log rank, p-value,0.0001 for all parameters). However,
protein expression of MRE11 (log rank, p = 0.867), Rad50 (log
rank, p = 0.986) and NBS1 (log rank, p = 0.991) was not associated
with overall survival. Moreover, sequencing of the poly(T)11 allele
of MRE11 in genomic DNA from EC tumours (n = 26; Table 2)
showed that mutations were more frequent in tumours with loss of
MRE11 than in those expressing MRE11, but the mutation status
was not highly predictive for the protein status of MRE11.
Loss of MRE11 is Associated with High Sensitivity to PARP
Inhibition
Among a panel of EC cell lines, AN3CA exhibited almost
complete MRE11 protein loss as well as markedly reduced levels of
RAD50 and NBS1 (Fig. 2A). Sequencing of the intronic region of
MRE11 in this cell line confirmed the previously described
homozygous poly(T)9 mutation in AN3CA (Fig. 2B) [11]. Upon
PARP-inhibitor treatment with BMN673, AN3CA shows the
highest sensitivity among the panel of endometrial cancer cell lines
tested (Fig. 3C).
Knock-down and Inhibition of MRE11 Sensitizes Cells to
BMN673 due to Impaired HR
Since loss of MRE11 expression in AN3CA was associated with
significant sensitivity to PARP inhibition, we asked if depletion of
Table 3. Association of MRE11 with RAD50, NBS1, mismatch repair protein status, and clinicopathological factors.
Variable Mre11 negative Mre11 positive p-value
RAD50 ,0.0001*
negative 87 18
positive 45 280
NBS1 ,0.0001*
negative 102 25
positive 29 266
MSH2/MSH6 ,0.0001*
negative 73 26
positive 54 249
MLH1/PMS2 ,0.0001*
negative 54 66
positive 76 215
FIGO stage 0.009**
I 55 160
II 17 40
III 29 42
IV 6 8
Histologic subtype 0.69**
endometrioid 113 248
serous 3 28
clear cell 6 7
undifferentiated 6 6
carcinosarcoma 4 9
Grading 0.019**
1 60 159
2 33 74
3 31 41
*Fisher’s Exact test;
**chi-square for trends.
doi:10.1371/journal.pone.0100041.t003
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MRE11 by siRNA would generally lead to an increased sensitivity
to the PARP-inhibitor BMN673. To test this we used a panel of
EC cell lines that expressed normal levels of MRE11 (Fig. 2A) and
were also resistant to PARP inhibition (Fig. 2C). The efficiency of
the siRNA treatment was evaluated by Western blotting. In both
cell lines, transfection with MRE11 siRNA efficiently depleted
endogenous MRE11 (Fig. 3A). We next assessed PARP inhibitor
sensitivity in the MRE11-depleted cells by colony formation. Upon
depletion of MRE11, we consistently observed a significant
decrease in cell viability in the presence of BMN673 (Fig. 3B).
In order to test if MRE11 nuclease activity is required for PARP
inhibitor resistance, we cultured two cell lines in the presence of
the MRE11 inhibitor mirin and treated them with BMN673
(Fig. 3C). In both cases mirin had a negative impact on the cell
viability in response to PARP inhibition, strongly suggesting that
MRE11 nuclease activity is required for PARP inhibitor
resistance. To confirm that knock down of MRE11 leads to
impaired HR, we determined the cells’ ability to form RAD51 foci
in response to ionizing radiation (IR) (see Fig. 4A). Indeed, upon
silencing of MRE11, fewer RAD51 foci per cell could be observed
(Fig. 4B). The Capan-1 pancreatic cell line known to be HR-
deficient due to a mutation of BRCA2 served as a control (data not
shown).
Discussion
This is the first report to show that not only the protein
expression of MRE11 but also the expression of the other
members of the MRN-complex, RAD50 and NBS1, are lost in a
substantial proportion of the ECs. Furthermore, we observed a
significant association between protein loss of all MRN members
as well as mismatch repair protein status in this large dataset.
Protein expression of the MRN-complex has not yet been studied
in EC tumours. In bladder cancer, MRE11 has been shown to
exhibit predictive properties for radiotherapy treatment [30].
Furthermore, complete loss of MRN-complex in MSI positive
colorectal cancers is a frequent event [31], whereas loss of MRE11
in breast tumours is found only in 9% of cases [32].
Although a clear correlation between mutational status and loss
of protein expression could not be found in this study, it is
remarkable that a high correlation of protein loss of all MRN
members as well as MSI status was found in this large dataset.
Confounding results on the mutational status of the MRE11
polyT(11) allele may be related to known difficulties in sequencing
of the MRE11 polyT(11) allele due to mispairing of the
polymerase enzyme [33].
A previous study revealed high frequency of alterations of DSB
repair genes in MSI positive ECs, where MRE11 and RAD50
exhibited heterozygous and homozygous mutations in 51% and
17%, respectively, without examining the impact of the loss of the
proteins [6]. Mutations of the MRE11 polyT(11) allele are
predominantly heterozygous mutations and it has been suggested
that only those with mutations of two and more nucleotides as well
as homozygous mutations have a functional impact in terms of loss
of function [11,12,34,35]. In this report, we cannot confirm the
high frequency of intronic mutations but provide evidence that
Figure 2. Endometrial carcinoma cell lines with loss of MRE11 show increased sensitivity to PARP inhibitors. A, Western blot
demonstrating the expression status of MRE11, NBS1 and RAD50 in 10 endometrial carcinoma cell lines. Only the cell line AN3CA harbours a mutation
of MRE11, which leads to a dramatically reduced expression of MRE11. Tubulin was used as loading control. B, Colony formation assays
demonstrating the sensitivity to the PARP inhibitor (BMN673) in 10 endometrial carcinoma cell lines: all cell lines were treated in triplicates for 14
days. Survival is represented in percentage of the control (DMSO treated). The cell colonies were quantified using a colorimetric method (SRB).
doi:10.1371/journal.pone.0100041.g002
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MRE11 protein is lost in a substantial proportion of ECs.
Recently, it has been shown that whole exon sequencing of
MRE11 revealed mutations in 1.9% (2 of 107) of the EC tumours
within the exons [36]. However, intronic mutations have not been
assessed, explaining why the frequency of MRE11 mutations is
reported to be low not only in the study by Price et al. [36] but also
in a recent one by The Cancer Genome Atlas Research Network
[5].
PARP inhibitors have shown remarkable sensitivity in BRCA1/
2-deficient tumour models in vitro as well as in clinical trials
involving carriers of BRCA1/2 germ line mutations. Further
evolving evidence, however, suggests the potential for a broader
scope for PARP inhibitor activity [16]. In fact, for EC we have
previously proposed loss of PTEN expression as a potential
biomarker for the treatment with PARP-inhibitors based on
preclinical data [26] as well as on a clinical case report [37]. Other
studies however, have been questioning the role of PTEN in HR,
suggesting that this might be a cell line specific phenomenon
[38,39]. Nevertheless, the exact mechanism of the involvement of
PTEN in HR DNA repair remains to be elucidated.
Loss of MRE11 expression has been suggested to sensitize
colorectal [35,38,40], breast [41] and haematological [42] cancer
cell lines to PARP-inhibitors due to impaired HR DNA repair.
Our report suggests, for the first time, the potential use of PARP
inhibitors in the treatment of endometrial cancer based on
preclinical findings. There is increasing evidence that patients
suffering from endometrial cancer and not expressing MRE11
could be treated with BMN673. This supports the use of MRE11
as a predictive biomarker for PARP treatment.
In conclusion, this study shows that i) complete loss of the MRN
complex is a frequent event in EC, ii) loss of MRE11 expression as
well as gene silencing and pharmacological inhibition of the
nuclease activity leads to sensitivity to PARP-inhibition in vitro, and
iii) loss of MRE11 is associated with deficient HR DNA repair
demonstrated upon irradiation. Based on these findings, we
propose that MRE11 expression may be used as a potential
predictive biomarker for the effectiveness of PARP inhibitor
treatment in endometrial cancers with MSI.
Figure 3. Decrease in MRE11 expression and function leads to increased sensitivity towards PARP inhibition in endometrial
carcinoma cell lines. A, Efficiency of siRNAs at different time points after transfection shown by western blotting. B, Sensitivity assay (colorimetric
with SRB): all cell lines were treated with PARP inhibitor (BMN673) in triplicates for 14 days. Survival is represented in percentage of the control (DMSO
treated). Knock down of MRE11 with three different sets of siRNAs lead to an increased sensitivity towards PARP inhibition in the endometrial
carcinoma cell lines HEC1A (8-fold increase, p,0.0001) and HEC-116 (6-fold increase, p = 0.0006). C, Cell lines were treated with the MRE11-inhibitor
mirin at a final concentration of 30 mM in triplicates for 10 days. Survival was assessed by a colorimetric sensitivity assay (SRB) and is shown in
percentage of the control (DMSO treated). Treatment with the MRE11-inhibitor mirin lead to increased sensitivity to PARP inhibition in both, HEC1A
(2.6-fold increase, p = 0.001) and HEC-116 (17-fold increase, p,0.0001).
doi:10.1371/journal.pone.0100041.g003
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